IL-10-secreting engineered macrophages alleviate DSS-induced colitis with macrophage phenotypic modulation and gut microbiota remodeling in mice.
4 affiliations
- 1Chinese PLA Medical School Beijing China.
- 2Department of Gastroenterology and Hepatology The First Medical Center of PLA General Hospital Beijing China.
- 3Research Center of Bioengineering, The Medical Innovation Research Division of PLA General Hospital Beijing China.
- 4The Medical School of Nankai University Tianjin China.
Abstract
Ulcerative colitis (UC) is a chronic recurrent inflammatory bowel disease characterized by abdominal pain, hematochezia, and weight loss. Although remarkable progress has been made toward understanding the pathogenesis of UC, finding more effective treatments for this disease remains a challenge. Interleukin-10 (IL-10) possesses potent anti-inflammatory properties, yet its therapeutic application in UC has failed clinically due to poor targeting and a short half-life. In this study, we developed IL-10-secreting engineered macrophages (IL-10M) based on RAW264.7 cells and evaluated their therapeutic effects in a dextran sulfate sodium-induced colitis model. Intraperitoneal administration of IL-10M alleviated body weight loss, disease activity, colon shortening, and histological injury. IL-10M also reduced mucosal damage and improved tight junction-associated epithelial barrier markers. Flow cytometry further detected engineered macrophage-associated GFP signals in colonic tissues and revealed an early increase in CD206⁺ endogenous colonic macrophages. Microbiome profiling showed treatment-associated compositional changes, including alterations in Bacteroides acidifaciens and Mucispirillum schaedleri, indicating microbiota remodeling after engineered macrophage treatment. Short-term safety assessment did not reveal overt hematological abnormalities or major histological injury in liver and spleen. Overall, these findings suggest that IL-10-secreting engineered macrophages may represent a promising macrophage-based strategy for mitigating intestinal inflammation in experimental colitis.
Related
- TGFB1-Engineered Induced Mesenchymal Stromal Cells Exhibit High Immunomodulatory Potency and Durably Reprogram Synovial Macrophages in Osteoarthritis
- Butyrate reverts Chlamydia pneumoniae -induced transcriptional suppression of macrophage polarization markers and promotes chlamydial clearance in macrophages
- Engineered Inflammation-Triggering Macrophages (MacTrigger) Synergize Anti-CD47 Immunotherapy While Sparing Normal Tissues
- Antibodies with Engineered Fc Domains Having Absolute Binding Selectivity to either FcγRIIa or FcγRI Delineate the Respective Effector Phenotypes by Human Monocytes and Macrophages
- Intestinal microbiota-associated LysoPC(16:0) promotes endometriosis via PPARγ-mediated M2 macrophage polarization and IL-10 secretion
BibTeX
@article{liu2026il10secreting,
title = {{IL-10-secreting engineered macrophages alleviate DSS-induced colitis with macrophage phenotypic modulation and gut microbiota remodeling in mice.}},
author = {Hanfei Liu and Junhua Liu and Shuhuang Peng and Jiwei Zhao and Fumeng Yang and Linwei Zhang and Shufang Wang and Luo Zhang and Gang Sun},
journal = {Bioengineering \& translational medicine},
year = {2026},
month = oct,
doi = {10.1002/btm2.70178},
url = {https://europepmc.org/article/MED/42923814},
note = {CC BY},
}
RIS
TY - JOUR
TI - IL-10-secreting engineered macrophages alleviate DSS-induced colitis with macrophage phenotypic modulation and gut microbiota remodeling in mice.
AU - Hanfei Liu
AU - Junhua Liu
AU - Shuhuang Peng
AU - Jiwei Zhao
AU - Fumeng Yang
AU - Linwei Zhang
AU - Shufang Wang
AU - Luo Zhang
AU - Gang Sun
PY - 2026
DA - 2026/10/22
JO - Bioengineering & translational medicine
DO - 10.1002/btm2.70178
UR - https://europepmc.org/article/MED/42923814
AB - Ulcerative colitis (UC) is a chronic recurrent inflammatory bowel disease characterized by abdominal pain, hematochezia, and weight loss. Although remarkable progress has been made toward understanding the pathogenesis of UC, finding more effective treatments for this disease remains a challenge. Interleukin-10 (IL-10) possesses potent anti-inflammatory properties, yet its therapeutic application in UC has failed clinically due to poor targeting and a short half-life. In this study, we developed IL-10-secreting engineered macrophages (IL-10M) based on RAW264.7 cells and evaluated their therapeutic effects in a dextran sulfate sodium-induced colitis model. Intraperitoneal administration of IL-10M alleviated body weight loss, disease activity, colon shortening, and histological injury. IL-10M also reduced mucosal damage and improved tight junction-associated epithelial barrier markers. Flow cytometry further detected engineered macrophage-associated GFP signals in colonic tissues and revealed an early increase in CD206⁺ endogenous colonic macrophages. Microbiome profiling showed treatment-associated compositional changes, including alterations in Bacteroides acidifaciens and Mucispirillum schaedleri, indicating microbiota remodeling after engineered macrophage treatment. Short-term safety assessment did not reveal overt hematological abnormalities or major histological injury in liver and spleen. Overall, these findings suggest that IL-10-secreting engineered macrophages may represent a promising macrophage-based strategy for mitigating intestinal inflammation in experimental colitis.
SN - 2380-6761
ER -